JAKAVI reduced spleen volume in the majority of patients
Demonstrated improvement in patients with enlarged spleen size1-3
- 38% of patients in the JAKAVI arm met the spleen response criterion (≥35% reduction in volume at Week 32) vs 1% in the BAT arm1,2
- Spleen response (spleen volume reduction ≥35%) was one of the components of the composite primary endpoint1,2
Change in spleen volume in each patient3

- Spleen size reduced in nearly three-quarters of all patients receiving JAKAVI3
- Proportion of patients with any spleen size reduction was an exploratory analysis
- Spleen volume ≥450 cm3 was included in the eligibility criteria for the trial1